Dementia and Neurocognitive Disorders (대한치매학회지)

Korean Dementia Association (대한치매학회)
권호 표지
DOI QR코드

DOI QR Code

Executive Summary of 2023 International Conference of the Korean Dementia Association (IC-KDA 2023): A Report From the Academic Committee of the Korean Dementia Association

  • Geon Ha Kim (Department of Neurology, Ewha Womans University Mokdong Hospital, Ewha Womans University, College of Medicine) ;
  • Jaeho Kim (Department of Neurology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine) ;
  • Won-Seok Choi (School of Biological Sciences and Technology, College of Natural Sciences, Chonnam National University) ;
  • Yun Kyung Kim (Brain Science Institute, Korea Institute of Science and Technology) ;
  • Kun Ho Lee (Department of Biomedical Science, Chosun University) ;
  • Jae-Won Jang (Department of Neurology, Kangwon National University Hospital, Kangwon National University School of Medicine) ;
  • Jae Gwan Kim (Department of Biomedical Science and Engineering, Gwangju Institute of Science and Technology) ;
  • Hui Jin Ryu (Department of Neurology, Konkuk University Medical Center) ;
  • Soh-Jeong Yang (Department of Neurology, Severance Hospital of Yonsei University Health System) ;
  • Hyemin Jang (0Department of Neurology, Seoul National University Hospital, Seoul National University College of Medicine) ;
  • Na-Yeon Jung (Department of Neurology, Pusan National University Yangsan Hospital, Pusan National University School of Medicine) ;
  • Ko Woon Kim (Department of Neurology, Jeonbuk National University Medical School and Hospital) ;
  • Yong Jeong (Department of Bio and Brain Engineering, Korea Advanced Institute of Science and Technology) ;
  • So Young Moon (Department of Neurology, Ajou University School of Medicine) ;
  • Academic Committee of the Korean Dementia Association (the Korean Dementia Association)
  • Received : 2024.03.02
  • Accepted : 2024.04.10
  • Published : 2024.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The Korean Dementia Association (KDA) has been organizing biennial international academic conferences since 2019, with the International Conference of the KDA (IC-KDA) 2023 held in Busan under the theme 'Beyond Boundaries: Advancing Global Dementia Solutions.' The conference comprised 6 scientific sessions, 3 plenary lectures, and 4 luncheon symposiums, drawing 804 participants from 35 countries. Notably, a Korea-Taiwan Joint Symposium addressed insights into Alzheimer's disease (AD). Plenary lectures by renowned scholars explored topics such as microbiome-related AD pathogenesis, social cognition in neurodegenerative diseases, and genetic frontotemporal dementia (FTD). On the first day, specific presentations covered subjects like the gut-brain axis and neuroinflammation in dementia, blood-based biomarkers in AD, and updates in AD therapeutics. The second day's presentations addressed recent issues in clinical neuropsychology, FTD cohort studies, and the pathogenesis of non-AD dementia. The Academic Committee of the KDA compiles lecture summaries to provide comprehensive understanding of the advanced dementia knowledge presented at IC-KDA 2023.

Keywords

Acknowledgement

The authors thank all members of the academic committee of Korean Dementia Association: So Young Moon, Kunho Lee, Hui Jin Ryu, Geon Ha Kim, Jaeho Kim, Jae-Won Jang, Hee-Jin Kim, Chi-Hun Kim, Ko Woon Kim, Jeewon Suh, Hyemin Jang, Young Ho Park, Byong Seok Ye, Na-Yeon Jung, Yun Kyung Kim, Yong Jeong, Jae Gwan Kim, Won-Seok Choi, Soh-Jeong Yang, and Juhee Chin

References

  1. Byrd AL, Segre JA. Infectious disease. Adapting Koch's postulates. Science 2016;351:224-226. https://doi.org/10.1126/science.aad6753
  2. Dominy SS, Lynch C, Ermini F, Benedyk M, Marczyk A, Konradi A, et al. Porphyromonas gingivalis in Alzheimer's disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 2019;5:eaau3333.
  3. Park SH, Lee JH, Kim JS, Kim TJ, Shin J, Im JH, et al. Fecal microbiota transplantation can improve cognition in patients with cognitive decline and Clostridioides difficile infection. Aging (Albany NY) 2022;14:6449-6466. https://doi.org/10.18632/aging.204230
  4. Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 2017;549:523-527. https://doi.org/10.1038/nature24016
  5. Seo DO, O'Donnell D, Jain N, Ulrich JD, Herz J, Li Y, et al. ApoE isoform- and microbiota-dependent progression of neurodegeneration in a mouse model of tauopathy. Science 2023;379:eadd1236.
  6. Xiong J, Zhang Z, Ye K. C/EBPβ/AEP signaling drives Alzheimer's disease pathogenesis. Neurosci Bull 2023;39:1173-1185. https://doi.org/10.1007/s12264-023-01025-w
  7. Xia Y, Qadota H, Wang ZH, Liu P, Liu X, Ye KX, et al. Neuronal C/EBPβ/AEP pathway shortens life span via selective GABAnergic neuronal degeneration by FOXO repression. Sci Adv 2022;8:eabj8658.
  8. Hu Y, Kirmess KM, Meyer MR, Rabinovici GD, Gatsonis C, Siegel BA, et al. Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment. JAMA Netw Open 2022;5:e228392.
  9. Fogelman I, West T, Braunstein JB, Verghese PB, Kirmess KM, Meyer MR, et al. Independent study demonstrates amyloid probability score accurately indicates amyloid pathology. Ann Clin Transl Neurol 2023;10:765-778.
  10. Liu HC, Chen HH, Ho CS, Chang JF, Lin CC, Chiu MJ, et al. Investigation of the number of tests required for assaying plasma biomarkers associated with Alzheimer's disease using immunomagnetic reduction. Neurol Ther 2021;10:1015-1028. https://doi.org/10.1007/s40120-021-00280-1
  11. Chiu PY, Yang FC, Chiu MJ, Lin WC, Lu CH, Yang SY. Relevance of plasma biomarkers to pathologies in Alzheimer's disease, Parkinson's disease and frontotemporal dementia. Sci Rep 2022;12:17919.
  12. Wang MJ, Yi S, Han JY, Park SY, Jang JW, Chun IK, et al. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease. Alzheimers Res Ther 2017;9:98.
  13. Babapour Mofrad R, Scheltens P, Kim S, Kang S, Youn YC, An SS, et al. Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status. Alzheimers Res Ther 2021;13:133.
  14. Cummings J, Fox N. Defining disease modifying therapy for Alzheimer's disease. J Prev Alzheimers Dis 2017;4:109-115. https://doi.org/10.14283/jpad.2017.12
  15. Van Dam D, De Deyn PP. Drug discovery in dementia: the role of rodent models. Nat Rev Drug Discov 2006;5:956-970. https://doi.org/10.1038/nrd2075
  16. Cummings J, Lee G, Nahed P, Kambar ME, Zhong K, Fonseca J, et al. Alzheimer's disease drug development pipeline: 2022. Alzheimers Dement (N Y) 2022;8:e12295.
  17. Salloway S, Chalkias S, Barkhof F, Burkett P, Barakos J, Purcell D, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol 2022;79:13-21. https://doi.org/10.1001/jamaneurol.2021.4161
  18. Esmaeili A, Eteghadi A, Landi FS, Yavari SF, Taghipour N. Recent approaches in regenerative medicine in the fight against neurodegenerative disease. Brain Res 2024;1825:148688.
  19. Kaur R, Singh AK, Singh DK, Singh S. Modern tools of genome engineering and their applications. In: Sobti RC, Kuhad RC, Lal R, Rishi P, editors. Role of Microbes in Sustainable Development: Human Health and Diseases. Singapore: Springer Nature Singapore, 2023;193-232.
  20. Purushotham SS, Buskila Y. Astrocytic modulation of neuronal signalling. Front Netw Physiol 2023;3:1205544.
  21. Verhoog QP, Holtman L, Aronica E, van Vliet EA. Astrocytes as guardians of neuronal excitability: mechanisms underlying epileptogenesis. Front Neurol 2020;11:591690.
  22. Berron D, Ziegler G, Vieweg P, Billette O, Gusten J, Grande X, et al. Feasibility of digital memory assessments in an unsupervised and remote study setting. Front Digit Health 2022;4:892997.
  23. Kwak S, Oh DJ, Jeon YJ, Oh DY, Park SM, Kim H, et al. Utility of machine learning approach with neuropsychological tests in predicting functional impairment of Alzheimer's disease. J Alzheimers Dis 2022;85:1357-1372. https://doi.org/10.3233/JAD-215244
  24. Staffaroni AM, Taylor JC, Clark AL, Heuer HW, Forsberg LK, Bahl R, et al. A remote smartphone cognitive testing battery for frontotemporal dementia: completion rate, reliability, and validity. Alzheimers Dement 2021;17:e056136.
  25. Rankin KP. Brain networks supporting social cognition in dementia. Curr Behav Neurosci Rep 2020;7:203-211. https://doi.org/10.1007/s40473-020-00224-3
  26. Dimitriou T, Parthimos T, Kamtsadeli V, Tsinia N, Hatzopoulou M, Lykou E, et al. The assessment of the socioemotional disorder in neurodegenerative diseases with the Revised Self-Monitoring Scale (RSMS). J Clin Med 2022;11:7375.
  27. Rijpma MG, Montembeault M, Shdo S, Kramer JH, Miller BL, Rankin KP. Semantic knowledge of social interactions is mediated by the hedonic evaluation system in the brain. Cortex 2023;161:26-37. https://doi.org/10.1016/j.cortex.2022.12.015
  28. Rohrer JD, Boxer AL. The frontotemporal dementia prevention initiative: linking together genetic frontotemporal dementia cohort studies. Adv Exp Med Biol 2021;1281:113-121. https://doi.org/10.1007/978-3-030-51140-1_8
  29. Boeve B, Bove J, Brannelly P, Brushaber D, Coppola G, Dever R, et al. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimers Dement 2020;16:22-36. https://doi.org/10.1016/j.jalz.2019.06.4947
  30. Ullgren A, Oijerstedt L, Olofsson J, Bergstrom S, Remnestal J, van Swieten JC, et al. Altered plasma protein profiles in genetic FTD - a GENFI study. Mol Neurodegener 2023;18:85.
  31. Rojas JC, Wang P, Staffaroni AM, Heller C, Cobigo Y, Wolf A, et al. Plasma neurofilament light for prediction of disease progression in familial frontotemporal lobar degeneration. Neurology 2021;96:e2296-e2312.
  32. Gendron TF, Heckman MG, White LJ, Veire AM, Pedraza O, Burch AR, et al. Comprehensive crosssectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Rep Med 2022;3:100607.
  33. Taylor JC, Heuer HW, Clark AL, Wise AB, Manoochehri M, Forsberg L, et al. Feasibility and acceptability of remote smartphone cognitive testing in frontotemporal dementia research. Alzheimers Dement (Amst) 2023;15:e12423.
  34. Barker MS, Manoochehri M, Rizer SJ, Appleby BS, Brushaber D, Dev SI, et al. Recognition memory and divergent cognitive profiles in prodromal genetic frontotemporal dementia. Cortex 2021;139:99-115. https://doi.org/10.1016/j.cortex.2021.03.006
  35. Seo JS, Lee S, Shin JY, Hwang YJ, Cho H, Yoo SK, et al. Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy. Exp Mol Med 2017;49:e333.
  36. Lee SJ, Lim HS, Masliah E, Lee HJ. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 2011;70:339-348. https://doi.org/10.1016/j.neures.2011.05.008
  37. Lee J, Sung KW, Bae EJ, Yoon D, Kim D, Lee JS, et al. Targeted degradation of α-synuclein aggregates in Parkinson's disease using the AUTOTAC technology. Mol Neurodegener 2023;18:41.
  38. Khan M, Chen XX, Dias M, Santos JR, Kour S, You J, et al. Differential effects of MATR3 variants on its cryptic splicing repression function. bioRxiv. 2023.
  39. Kao CS, van Bruggen R, Kim JR, Chen XX, Chan C, Lee J, et al. Selective neuronal degeneration in MATR3 S85C knock-in mouse model of early-stage ALS. Nat Commun 2020;11:5304.